Evaluation of Oxidative DNA Damage and Immunity Markers as Predicate of Prostate Patients
Keywords:
Predicator markers, oxygen species, Prostate cancer, cytokinesAbstract
Problems in health male accounts for 50% of all occurrences of infertility and is the only cause of 10–30% of cases. Male-specific malignancies and reproductive problems have become a major public health concern due to their sharp rise in recent years.
Study Aim: In this research, the levels of some different biomarkers will be investigated –Prostatic Acid Phosphatase (PAP), Prostate Cancer Gene 3 (PCA3), reactive oxygen species 8-hydroxy-2'-deoxyguanosine (8-OHDG), and immunological cytokines including IL-18 and prostate specific antigen (PSA) at the fertility center as a diagnostic marker of hyperplasis between patients who were infertile due to prostate cancer, patients who had prostatic hyperplasia, and healthy individuals who were fertile controls.
Material and methods: The study involved 100 males, choose 80 divided into 58 prostate hyperplasia male infertile, 10 fertile control male and 22 patients' prostatic cancer infertile visit the fertility center and Doctor's Consulting Clinic in peroid between 1/11/2024 to 1/3/2025.
Results: Significant differences in biomarker levels were observed across the groups. The levels of IL-18, PSA, PAP, and PCA3 were also considerably higher in patients with hyperplasia and cancer when compared to the levels seen in controls (The p-value for PAP was less than 0.01, the p-value for PCA3 was less than 0.002, and the p-value for IL-18 was less than 0.001). Notably, 8-OHDG levels were significantly lower in hyperplasia and cancer groups compared to controls (p < 0.05). While mean values for PCA3 and IL-18 were higher in cancer than hyperplasia, these differences did not reach statistical significance also, PAP demonstrated clear differences between all three groups and 8-OHDG was significantly lower in disease groups compared to controls.
Conclusion: These results suggest that, 8-OHDG, PAP, PCA3, PSA, and IL-18 may serve as valuable biomarkers for differentiating between healthy individuals, those with prostatic hyperplasia, and those with prostate cancer.
Recommendation: These biomarkers have potential clinical utility in distinguishing prostate health and disease states, conduct more in-depth studies to explore the relationship between BMI and P. Hyperplasia/Cancer 8-OHDG, PAP, PCA3, PSA, and IL-18 and investigate potential mechanisms, such as hormonal influences, inflammatory markers, and metabolic factors.
Downloads
References
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023). Unlocking the mystery associated with infertility and prostate cancer: an update. Medical Oncology, 40(6), 160. https://doi.org/10.1007/s12032-023-02028-3.
Kasman, A. M., Del Giudice, F., & Eisenberg, M. L. (2020). New insights to guide patient care: the bidirectional relationship between male infertility and male health. Fertility and Sterility, 113(3), 469–477.
Bell, K. J. L., Del Mar, C., Wright, G., Dickinson, J., & Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International Journal of Cancer, 137(7), 1749–1757.
Bratt, O., Drevin, L., Akre, O., Garmo, H., & Stattin, P. (2016). Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. Journal of the National Cancer Institute, 108(10), djw110.
Leitzmann, M. F., & Rohrmann, S. (2012). Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clinical Epidemiology, 1–11.
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2016). Cancer genomics: diversity and disparity across ethnicity and geography. Journal of Clinical Oncology, 34(1), 91–101.
Sullivan, L. M. (2023). Essentials of biostatistics in public health. Jones & Bartlett Learning.
World Health Organization (WHO) (2019) Coronavirus disease (COVID-19) - Weekly Epidemiological Update - 23 August 2020.
Al-Fartosy A J M, Awad N A and Mahmood R A (2019) A Comparative Study of Leptin, Oxidant/Antioxidant Status and Some Trace Elements in Women of Healthy Control and Unexplained Infertility in Basrah-Iraq. Indonesia Biomed J. 11(3), 327-337.
Zazzo E D, Galasso G, Giovannelli P, Donato M D and Castoria G (2018) Estrogen and their receptors in prostate cancer: Therapeutic implication. Front Oncol. 8(2), 1-7.
Al-Fartosy A J M, Awad N A and Alsalimi S A (2021) Clinical markers and some trace elements in patients with type-2 diabetic nephropathy: Impact of insulin resistance. J. Med. Invest. 68(1), 76-84.
Rodriguez JF, Eggener SE. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018;56:187-96.
Smits M, Mehra N, Sedelaar M, Gerritsen W, Schalken JA. Molecular biomarkers to guide precision medicine in localized prostate cancer. Expert Rev Mol Diagn. 2017;17:791-804.
Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2011;301:1-6.
Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6:255-61.
Marks LS, Bostwick DG. Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Rev Urol. 2008;10:175-81.
Vendrell I, Macedo D, Alho I, Dionísio M R and Costa L (2015) Treatment of Cancer Pain by Targeting Cytokines. Mediat. Inflam. 2015, 1-11.
Srinivasan S, Stephens C, Wilson E, Panchadsaram J, DeVoss K, Koistinen H, Stenman U, Brooks M, Buckle A M, Klein R J, Lilja H, Clements J and Batra J (2019) Prostate cancer risk associated Single Nucleotide Polymorphism affects PSA glycosylation and its function. Clin. 65(1), 1-9.
Jorgovanovic D, Song M, Wang L and Zhang Y (2020) Roles of IFN- g in tumor progression and regression: a review. Biomark. Res. 8(49), 1-16.
Fu S, Chien M, Hsu C, Liu Y and Sytwu H (2020) Interplay between cytokine circuitry and transcriptional regulation shaping helper T cell pathogenicity and plasticity in inflammatory bowel disease. Int. J. Mol. Sci. 21(3379), 1-23.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
